BCPEM
PBYI icon

Bain Capital Public Equity Management’s Puma Biotechnology PBYI Stock Holding History

Bain Capital Public Equity Management’s Portfolio PBYI Stock Details PBYI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-4,700
Closed -$1.45M – 92
2017
Q4 		$1.45M Buy
+4,700
New +$526K 0.11% 61

Other funds holding PBYI

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Bain Capital Public Equity Management's PBYI Position: Q4 2017 in Review

Bain Capital Public Equity Management sold out of Puma Biotechnology (PBYI) in Q4 2017, closing a stake of 657,876 shares — an estimated $73.6M sold.

Bain Capital Public Equity Management first reported a position in PBYI in Q2 2013 and held it in 6 quarters. The position peaked at $78.8M in Q3 2017. 203 funds tracked by Wall St. Rank hold PBYI as of Q4 2017.

  • Bain Capital Public Equity Management reported no remaining Puma Biotechnology position as of Q4 2017 after selling out during the quarter.
  • Bain Capital Public Equity Management sold 657,876 Puma Biotechnology shares in Q4 2017, an estimated $73.6M.
  • Bain Capital Public Equity Management first reported a position in Puma Biotechnology in Q2 2013 and held it in 6 quarters.
  • Bain Capital Public Equity Management's Puma Biotechnology position peaked at $78.8M in Q3 2017.
  • 203 funds tracked by Wall St. Rank held Puma Biotechnology as of Q4 2017.

Based on Bain Capital Public Equity Management's 13F filing for Q4 2017, filed 14 Feb 2018.